Divi's Laboratories Limited Stock Price Today (NSE: DIVISLAB)
Fundamental Score
Divi's Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Divi's Laboratories Limited share price today is ₹8588.00, up +1.31% on NSE/BSE as of 24 August 2026. Divi's Laboratories Limited (DIVISLAB) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.93L (Cr). The 52-week high for DIVISLAB share price is ₹8674.00 and the 52-week low is ₹5636.50. At a P/E ratio of 73.64x, DIVISLAB is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 16.53% and a debt-to-equity ratio of 0.00.
Divi's Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Divi's Laboratories Limited share price chart: 8.83% return over the past month. 52-week high ₹8674.00, 52-week low ₹5636.50.
Divi's Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹8510.00 | ₹8630.00 | ₹8504.00 | ₹8588.00 | 4.04L (Cr) | |
| ₹8499.50 | ₹8574.50 | ₹8465.50 | ₹8477.00 | 3.40L (Cr) | |
| ₹8539.50 | ₹8539.50 | ₹8414.00 | ₹8500.00 | 3.44L (Cr) | |
| ₹8630.00 | ₹8674.00 | ₹8471.50 | ₹8600.00 | 5.57L (Cr) | |
| ₹8315.00 | ₹8578.50 | ₹8285.50 | ₹8578.50 | 6.04L (Cr) | |
| ₹8285.00 | ₹8350.00 | ₹8258.50 | ₹8300.00 | 3.80L (Cr) | |
| ₹8285.50 | ₹8334.00 | ₹8233.50 | ₹8275.00 | 2.57L (Cr) | |
| ₹8408.00 | ₹8448.00 | ₹8268.50 | ₹8349.00 | 3.27L (Cr) | |
| ₹8389.50 | ₹8441.00 | ₹8333.00 | ₹8388.00 | 3.17L (Cr) | |
| ₹8451.00 | ₹8460.50 | ₹8243.00 | ₹8378.00 | 9.70L (Cr) |
Divi's Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹8380.00 | ₹8674.00 | ₹8105.00 | ₹8588.00 | +2.48% | |
| ₹6599.00 | ₹8090.00 | ₹6530.50 | ₹8056.00 | +22.08% | |
| ₹6690.00 | ₹6887.50 | ₹6450.50 | ₹6579.00 | -1.66% | |
| ₹6508.00 | ₹6968.00 | ₹6483.50 | ₹6667.00 | +2.44% | |
| ₹6002.00 | ₹6549.50 | ₹5647.50 | ₹6502.50 | +8.34% | |
| ₹6271.50 | ₹6479.00 | ₹5901.50 | ₹5947.00 | -5.17% | |
| ₹6056.00 | ₹6793.00 | ₹5890.00 | ₹6408.50 | +5.82% | |
| ₹6398.00 | ₹6731.50 | ₹5955.00 | ₹6051.00 | -5.42% | |
| ₹6500.50 | ₹6598.00 | ₹6265.00 | ₹6392.50 | -1.66% | |
| ₹6738.00 | ₹6904.50 | ₹6322.00 | ₹6477.00 | -3.87% | |
| ₹5692.50 | ₹6775.00 | ₹5675.00 | ₹6738.00 | +18.37% | |
| ₹6131.50 | ₹6280.00 | ₹5636.50 | ₹5689.50 | -7.21% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Divis is an API pure play trading at nosebleed valuations; execution needs to be flawless.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Divis Laboratories' stock has shown mixed performance recently. On April 2, 2026, the stock was down 1.39% to , marking its fifth straight session of decline. However, the stock had jumped 1.07% in the past year, outperforming the NIFTY. Recent news indicates that the company has scheduled its Q4 FY26 results for May 15, 2026.
CORE STORY (THE REAL GAME)
Divis is an API powerhouse, and the real game is its ability to capitalize on custom synthesis and generic API opportunities, especially with the expected entry of GLP-1 drugs and increased revenues from contrast media products.
- GLP-1 drug opportunity in 2026
- Strong custom synthesis growth
- Robust export growth
- Positive Q4 FY26 results
- Constructive FY27 guidance
- New long-term manufacturing agreements
- High valuation
- Concentration in a few molecules
- US generics pricing pressure
FII decreased by 0.35%, DII increased by 0.72% [cite: brief]
Indian pharma industry is projected to reach $130 billion by 2030, driven by expanding global demand and innovation.
Yes, Free Cash Flow 5Y: ₹4695.21 Cr [cite: brief]
Divis's near-term performance hinges on Q4 results and FY27 guidance. Success in GLP-1 drugs and custom synthesis will be key to sustaining growth.
Primary Thesis Risk
Failure to capitalize on GLP-1 drug opportunities and custom synthesis growth.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Divi's Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Divi's Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DIVISLAB across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (16.53%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.96%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (33.44%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (151.52x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 6.94)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹3879.32 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.89%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 39.42%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 73.64x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (15.23x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Divi's Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Divi's Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Divi's Laboratories LimitedDivi's Laborato...Selected✓ DIVISLAB • 532488 | 56.3/100 | ₹8588.00₹8588 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1415.10₹1415 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Biocon LtdBiocon Ltd... BIOCON • 532523 | 30.2/100 | ₹437.95₹438 | ₹70826.50₹70826.50 | 181.85Average 181.8 Average | 1.40%Poor 1.40% Poor | 3.75%Poor 3.75% Poor | 0.45Excellent 0.5 Excellent | -11.84%Poor -11.84% Poor | 18.83%Excellent 18.83% Excellent | 0.12% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 62.3/100 | ₹28900.00₹28900 | ₹58692.31₹58692.31 | 37.82Average 37.8 Average | 34.46%Excellent 34.46% Excellent | 44.89%Excellent 44.89% Excellent | 0.04Excellent 0.0 Excellent | 17.57%Excellent 17.57% Excellent | 9.96%Good 9.96% Good | 1.90% |
JB Chemicals & Pharmaceuticals LtdJB Chemicals & ... JBCHEPHARM • 506943 | 53.9/100 | ₹2408.90₹2409 | ₹40248.14₹40248.14 | 56.02Average 56.0 Average | 18.93%Good 18.93% Good | 25.45%Excellent 25.45% Excellent | 0.00Excellent 0.0 Excellent | 12.37%Good 12.37% Good | 15.22%Excellent 15.22% Excellent | 0.88% |
Wockhardt LtdWockhardt Ltd... WOCKPHARMA • 532300 | 24.6/100 | ₹1953.40₹1953 | ₹30725.07₹30725.07 | 108.16Average 108.2 Average | 6.11%Poor 6.11% Poor | 7.55%Poor 7.55% Poor | 0.45Excellent 0.5 Excellent | -19.25%Poor -19.25% Poor | 4.49%Average 4.49% Average | 0.00% |
ACUTAAS CHEMICALS LIMITEDACUTAAS CHEMICA... ACUTAAS • 543349 | 62.09999999999999/100 | ₹3659.60₹3660 | ₹29036.77₹29036.77 | 81.50Average 81.5 Average | 24.05%Excellent 24.05% Excellent | 31.56%Excellent 31.56% Excellent | 0.02Excellent 0.0 Excellent | 45.77%Excellent 45.77% Excellent | 31.50%Excellent 31.50% Excellent | 0.04% |
Sequent Scientific LtdSequent Scienti... SEQUENT • 512529 | 63.9/100 | ₹188.78₹189 | ₹12241.20₹12241.20 | 61.29Average 61.3 Average | 11.05%Average 11.05% Average | 19.05%Good 19.05% Good | 0.17Excellent 0.2 Excellent | 15.00%Excellent 15.00% Excellent | 20.23%Excellent 20.23% Excellent | 0.00% |
Aarti Pharmalabs LtdAarti Pharmalab... AARTIPHARM • 543748 | 9.1/100 | ₹672.70₹673 | ₹6511.24₹6511.24 | 36.83Average 36.8 Average | 8.59%Poor 8.59% Poor | 10.70%Average 10.70% Average | 0.36Excellent 0.4 Excellent | — — | — — | 0.70% |
38/100 | ₹1444.90₹1445 | ₹4726.65₹4726.65 | — — | -15.00%Poor -15.00% Poor | -8.47%Poor -8.47% Poor | 0.39Excellent 0.4 Excellent | — — | 38.41%Excellent 38.41% Excellent | 0.07% | |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
- Biocon Ltd share price70826.50 Cr
- Abbott India Ltd share price58692.31 Cr
- JB Chemicals & Pharmaceuticals Ltd share price40248.14 Cr
Divi's Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for DIVISLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹82.53 | ₹6392.50 | 77.5x |
| FY 2024 | ₹60.27 | ₹6098.80 | 101.2x |
| FY 2023 | ₹68.69 | ₹3903.90 | 56.8x |
| FY 2022 | ₹111.52 | ₹3413.20 | 30.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Divi's Laboratories Limited Dividend History
Annual cash dividends paid by DIVISLAB — dividend yield 0.41%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹796.00 Cr |
| FY 2024 | ₹796.00 Cr |
| FY 2023 | ₹796.00 Cr |
| FY 2022 | ₹530.94 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Divi's Laboratories Limited Quarterly Performance
Latest quarterly metrics for DIVISLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
9.52%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
13.44%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.67%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
5.71%
Compounded annual net profit growth over 5 years
Divi's Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DIVISLAB — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Divi's Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Divi's Laboratories Limited (DIVISLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Divi's Laboratories Limited
About DIVISLAB (Divi's Laboratories Limited)
Divis Laboratories Ltd is a prominent global pharmaceutical player, distinguished by its robust manufacturing capabilities and commitment to quality. As a leading manufacturer, the... company specializes in the production of active pharmaceutical ingredients (APIs), intermediates, and a diverse range of specialty chemicals. Divis is strategically positioned to meet the demands of the pharmaceutical industry across the world, adhering to stringent regulatory standards in key markets like North America, Europe, and Asia. Leveraging advanced technology and a highly skilled workforce, Divis operates state-of-the-art facilities focused on enhancing production efficiency and quality control. The company's focus on innovation and sustainability has enabled it to establish long-term partnerships with some of the largest pharmaceutical companies. Beyond its core API and intermediate business, Divis Laboratories Ltd has also diversified into custom manufacturing and synthesis, offering tailored solutions to meet specific client needs. The company's expertise in complex chemical processes and its agile manufacturing infrastructure make it an ideal partner for pharmaceutical companies seeking to outsource production or develop new chemical entities. Divis's custom synthesis capabilities support both early-stage research and development as well as commercial-scale manufacturing. This adaptability strengthens its position as a reliable and innovative solutions provider. The company's unwavering dedication to quality and customer satisfaction further fosters long-term relationships and drives sustained growth. Divis Laboratories Ltd also produces a range of nutraceutical ingredients that add considerable value to the company. These ingredients cater to a variety of consumer segments, including dietary supplements, food, and beverage industries. Divis is committed to research and development of value added products and continues to expand its portfolio. They are dedicated to meeting the increasing demand for health and wellness products.
Company Details
Key Leadership
Corporate Events
DIVISLAB Share Price: Frequently Asked Questions
What is the current share price of Divi's Laboratories Limited?
Divi's Laboratories Limited (DIVISLAB) trades at ₹8588.00 on NSE and BSE. Market cap ₹1.93L (Cr). Educational data only.
What is the P/E ratio of Divi's Laboratories Limited?
Divi's Laboratories Limited has a P/E of 73.64x vs industry average 34.89x.
What is the Bull Run score for Divi's Laboratories Limited?
Divi's Laboratories Limited has a Bull Run score of 56.3/100 based on 25+ financial parameters.
Does Divi's Laboratories Limited pay dividends?
Divi's Laboratories Limited has a dividend yield of 0.41%. Past dividends don't guarantee future payments.
What is the ROE of Divi's Laboratories Limited?
Divi's Laboratories Limited has ROE of 16.53%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Divi's Laboratories Limited?
Divi's Laboratories Limited has debt-to-equity of 0.00.
Is Divi's Laboratories Limited a good investment?
Bull Run gives Divi's Laboratories Limited a score of 56.3/100. This is not investment advice — consult a SEBI-registered advisor.